Since PSMA7 overexpression was validated due to amplification in clinical samples with different types of cancers, we further asked whether PSMA7 amplification showed poor response to these resistant agents, for instance, the first-ranking compound TPCA-150. The gene discussed is PSMA7; the disease is cancer.